An observational study in Acute Respiratory Distress Syndrome, sponsored by Sanatorio Anchorena San Martin. Recruiting at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Sanatorio Anchorena San Martin · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Respiratory Distress Syndrome with a site in Argentina — 6 open to participants now, 7 under way, 1 of them phase 3. Respiratory Distress Syndrome · Argentina.
Among the 21 studies in Respiratory Distress Syndrome with a site in Argentina, this one is the 8th largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2020, is one of 12 observational ones, and was the 11th registered.
1,388 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →6 of the 21 studies in Respiratory Distress Syndrome with a site in Argentina are open now. Recruiting first, the newest first:
Hospital de Alta Complejidad en Red · Sites in Argentina
Ages 1 mo–14 yrs
Pontificia Universidad Catolica de Chile · Sites in Argentina, Chile, Colombia and 3 more countries
Ages 18+
Hospital El Cruce · Sites in Argentina
Ages 18–75
AstraZeneca · Sites in Argentina, United States, Australia and 36 more countries
Ages 18+
Ramos Mejía Hospital · Sites in Argentina
Ages 15+
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 107 across the 9 interventional studies, 40 across the 12 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 21 have an industry lead sponsor. The 10 most frequent:
Sanatorio Anchorena San Martin is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Sanatorio Anchorena San Martin has 3 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Respiratory Distress Syndrome with a site in Argentina that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06854627Pontificia Universidad Catolica de ChileEffect of Continuous Prolonged Prone Position Versus Intermittent Daily Prone Position in ARDS | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Respiratory Distress Syndrome with a site in Argentina, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Spontaneous breathing during the transition from controlled to assisted ventilation in ARDS may be harmful, as high respiratory drive can generate large transpulmonary pressure swings and worsen lung injury. Higher PEEP may mitigate this by reducing inspiratory effort and lung stress, but patient response is variable and difficult to predict. While improved lung compliance appears to mediate the protective effects of PEEP, its bedside assessment is complex. Preclinical data suggest that changes in compliance are inversely reflected by changes in respiratory rate, but this relationship and its clinical utility in ARDS patients remain unclear.
Spontaneous Breathing (SB) can be potentially harmful in patient with Acute Respiratory Distress Syndrome (ARDS) during the transition phase of passive ventilation to partial ventilatory support. A high respiratory drive and consequently, a strong inspiratory effort, may produce large transpulmonary pressure (TP) swings mainly in dependent lung regions closer to the diaphragm and cause alveolar rupture and inflammatory mediators release.
The application of high Positive End Expiratory Pressure (PEEP) during SB has shown to ameliorate the progression of lung injury by decreasing the TP and esophageal pressure (EP) swings and the stress / strain applied to the lung. However, it is uncertain which patient will respond adequately to the application of high PEEP and consequently will reduce the inspiratory effort.
Recent evidence suggests that high PEEP may confer protective effects when lung compliance improves. However, assessing lung compliance at the bedside is challenging, as it requires esophageal pressure monitoring. Simpler tools to identify lung compliance response to PEEP are neccesary.
Preclinical data suggest that the changes in compliance are followed by opposite changes in respiratory rate (RR) - i.e., if compliance improves, RR decreases and vicerversa. However, if this behaviour is also observed in ARDS patients ventilated at different PEEP levels is unkown. Additionally, whether changes in RR can be useful to identify changes in lung compliance when increasing PEEP has never been tested.
Patients with acute respiratory distress syndrome ventilated using an endotracheal tube admitted to Anchorena San Martin intensive care unit who are ventilated in pressure support ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Initially, the patients will be ventilated using pressure support ventilation with an inspiratory pressure adjusted to achieve 6 - 8 ml/kg of PBW with a minimal esophageal pressure swing of 5 cmH2O and a PEEP of 5 cmH2O. After 5 minutes, we will collect basic and advanced respiratory monitoring, including esophageal pressure and transpulmonary pressure swings. The same procedure will be carried out with 10 and 15 cmH2O of PEEP. Inspiratory pressure will be kept constant throughout the protocol.
Lung compliance response
changes in lung compliance from one PEEP level to the subsequent higher level, expressed in percentage of change
Time frame: 10 minutes
Esophageal pressure swing
Esophageal pressure swing will be calculated as the difference between end expiration and end inspiration esophageal pressure during the las 30-60 seconds of each PEEP condition evaluated
Time frame: 10 minutes
Dynamic transpulmonary pressure swing
Dynamic transpulmonary pressure swing will be calculated as the difference between end expiration and end inspiration dynamic transpulmonary pressure during the las 30-60 seconds of each PEEP condition evaluated
Time frame: 10 minutes
Respiratory rate response
changes in respiratory rate from one PEEP level to the subsequent higher level, expressed in percentage of change
Time frame: 10 minutes
Plan to share: Undecided
Ran from Aug 2020 to primary completion in Apr 2026, 68 months.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 68 months is above that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Sanatorio Anchorena San Martin